


BioCryst Pharmaceuticals (Fri, May 03, 2024)

Sell candidate since Apr 12, 2024

Loss -6.71%

StockInvest.us
Gyneju st. 14, "ROCKIT"
Vilnius, LT-01109
Lithuania



score: **-3.26**
#16584/ 30044

Tech commentaries:

The **BioCryst Pharmaceuticals** stock price fell by **-0.670%** on the last day (Friday, 3rd May 2024) from **\$4.48** to **\$4.45**. During the last trading day the stock fluctuated **5.66%** from a day low at **\$4.42** to a day high of **\$4.67**. The price has fallen in 7 of the last 10 days but is still up by **0.45%** over the past 2 weeks. Volume has increased on the last day by **409 thousand** shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, **3 million** shares were bought and sold for approximately **\$11.73 million**.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall **-24.62%** during the next 3 months and, with a 90% probability hold a price between **\$3.03** and **\$3.57** at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

There are mixed signals in the stock today. The **BioCryst Pharmaceuticals** stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at **\$4.73**. On a fall, the stock will find some support from the short-term average at **\$4.32**. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely. A buy signal was issued from a pivot bottom point on **Tuesday, April 30, 2024**, and so far it has risen 7.75%. Further rise is indicated until a new top pivot has been found.

BioCryst Pharmaceuticals finds support from accumulated volume at **\$4.43** and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance from accumulated volume at **\$5.00**, **\$5.14** and **\$5.32**.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved **\$0.250** between high and low, or **5.66%**. For the last week, the stock has had daily average volatility of **7.04%**.

BioCryst Pharmaceuticals holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Risk: **Medium**

Evaluation: **Sell Candidate**

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.